Abstract
A sea level TCOM assessment has an accuracy of about 70%, while the accuracy of in-chamber TCOM approaches 75%. Even with these effective screening
tools, prediction would still be incorrect in one out of four cases and patients who
might benefit from HBO2T would be deprived of the therapy. Therefore, these
‘‘cut-off’’ scores must serve as guides to therapy. A rational approach might be
to provide a trial of therapy and then reassess the patient on the basis of clinical
progress or improved TCOM values after a reasonable trial of therapy (e.g., 15-20
treatments).